150 related articles for article (PubMed ID: 38250760)
1. EGFR, HLA-G, CD70, c-MET, and NY-ESO1 as potential biomarkers in high grade epithelial ovarian carcinoma.
Vo D; Liu Y; Sood AK; Rezvani K; Jazaeri AA; Liu J
Cancer Biomark; 2024; 39(4):289-298. PubMed ID: 38250760
[TBL] [Abstract][Full Text] [Related]
2. c-Met expression is a marker of poor prognosis in patients with locally advanced head and neck squamous cell carcinoma treated with chemoradiation.
Baschnagel AM; Williams L; Hanna A; Chen PY; Krauss DJ; Pruetz BL; Akervall J; Wilson GD
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):701-7. PubMed ID: 24521684
[TBL] [Abstract][Full Text] [Related]
3. Survival and biomarker analysis for ovarian mucinous carcinoma according to invasive patterns: retrospective analysis and review literature.
Hada T; Miyamoto M; Ishibashi H; Matsuura H; Sakamoto T; Kakimoto S; Iwahashi H; Tsuda H; Takano M
J Ovarian Res; 2021 Feb; 14(1):33. PubMed ID: 33583413
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Outcome of Mesenchymal Transition Biomarkers in Correlation with EGFR Expression in Epithelial Ovarian Carcinoma Patients.
Kamal IM; Temerik DF; Yassin EH; Mosad E; A H; Hussien MT
Asian Pac J Cancer Prev; 2022 Dec; 23(12):4213-4225. PubMed ID: 36580004
[TBL] [Abstract][Full Text] [Related]
5. HLA-G expression is an independent predictor for improved survival in high grade ovarian carcinomas.
Rutten MJ; Dijk F; Savci-Heijink CD; Buist MR; Kenter GG; van de Vijver MJ; Jordanova ES
J Immunol Res; 2014; 2014():274584. PubMed ID: 24987709
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of growth factor receptor EGFR and angiogenesis regulator VEGF‑R2 in patients with ovarian cancer at FIGO stages I-II.
Skirnisdottir I; Åkerud H; Seidal T
Int J Oncol; 2018 Oct; 53(4):1633-1642. PubMed ID: 30066848
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic significance of HLA-G and HLA-E molecules in Tunisian patients with ovarian carcinoma.
Babay W; Ben Yahia H; Boujelbene N; Zidi N; Laaribi AB; Kacem D; Ben Ghorbel R; Boudabous A; Ouzari HI; Rizzo R; Rebmann V; Mrad K; Zidi I
Hum Immunol; 2018 Jun; 79(6):463-470. PubMed ID: 29499226
[TBL] [Abstract][Full Text] [Related]
8. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma.
Chang B; Meng J; Zhu H; Du X; Sun L; Wang L; Li S; Yang G
Diagn Pathol; 2018 Nov; 13(1):87. PubMed ID: 30428884
[TBL] [Abstract][Full Text] [Related]
10. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging.
Skírnisdóttir I; Seidal T; Sorbe B
Int J Gynecol Cancer; 2004; 14(2):259-70. PubMed ID: 15086725
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of GPNMB predicts an unfavorable outcome of epithelial ovarian cancer.
Ma RQ; Tang ZJ; Ye X; Cheng HY; Sun KK; Chang XH; Cui H
Arch Gynecol Obstet; 2018 May; 297(5):1235-1244. PubMed ID: 29428978
[TBL] [Abstract][Full Text] [Related]
12. Combined CD44, c-MET, and EGFR expression in p16-positive and p16-negative head and neck squamous cell carcinomas.
Baschnagel AM; Tonlaar N; Eskandari M; Kumar T; Williams L; Hanna A; Pruetz BL; Wilson GD
J Oral Pathol Med; 2017 Mar; 46(3):208-213. PubMed ID: 27442811
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.
Matsuo K; Sheridan TB; Mabuchi S; Yoshino K; Hasegawa K; Studeman KD; Im DD; Rosenshein NB; Roman LD; Sood AK
Gynecol Oncol; 2014 Jun; 133(3):473-9. PubMed ID: 24674832
[TBL] [Abstract][Full Text] [Related]
14. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
[TBL] [Abstract][Full Text] [Related]
15. Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study.
Brunette LL; Mhawech-Fauceglia PY; Ji L; Skeate JG; Brand HE; Lawrenson K; Walia S; Chiriva-Internati M; Groshen S; Roman LD; Kast WM; Da Silva DM
BMC Cancer; 2018 Oct; 18(1):970. PubMed ID: 30309325
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological and survival characteristic of mismatch repair status in ovarian clear cell carcinoma.
Zhu J; Ke G; Bi R; Wu X
J Surg Oncol; 2020 Sep; 122(3):538-546. PubMed ID: 32396667
[TBL] [Abstract][Full Text] [Related]
17. Sprouty 2 protein, but not Sprouty 4, is an independent prognostic biomarker for human epithelial ovarian cancer.
Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
Int J Cancer; 2015 Aug; 137(3):560-70. PubMed ID: 25630587
[TBL] [Abstract][Full Text] [Related]
18. High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer.
Corvigno S; Mezheyeuski A; De La Fuente LM; Westbom-Fremer S; Carlson JW; Fernebro J; Åvall-Lundqvist E; Kannisto P; Hedenfalk I; Malander S; Rolny C; Dahlstrand H; Östman A
Gynecol Oncol; 2020 Dec; 159(3):860-868. PubMed ID: 33032823
[TBL] [Abstract][Full Text] [Related]
19. High expression of TRIM24 predicts worse prognosis and promotes proliferation and metastasis of epithelial ovarian cancer.
Zhang L; Chen H; Ding B; Jiang W
J Ovarian Res; 2022 Feb; 15(1):19. PubMed ID: 35105347
[TBL] [Abstract][Full Text] [Related]
20. Expression and Prognostic Significance of PD-L1 and NY-ESO1 in Gallbladder Carcinoma.
Ibukić A; Ramić S; Zovak M; Bilić Z; Tomas D; Demirović A
In Vivo; 2023; 37(4):1828-1837. PubMed ID: 37369470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
